“Genetic testing” is not one purchase. It is at least four separate markets that share a word, and the reason price quotes for it range from under $100 to nearly $2,500 is that people are comparing a saliva kit bought on sale against a clinician-ordered sequencing panel.
Sorting out which product you are buying does most of the work of figuring out what you should pay. This guide covers the four markets as of September 2026: hereditary cancer panels including BRCA1 and BRCA2, carrier screening before or during pregnancy, pharmacogenomic testing that looks at drug metabolism, and direct-to-consumer ancestry-plus-health kits, which are a different category of product and are not diagnostic.
What Does Genetic Testing Cost Without Insurance?
Prices below are published self-pay prices from each lab as of September 2026, alongside Medicare’s 2026 Clinical Laboratory Fee Schedule rates for the underlying CPT codes. The Medicare rates are not what you would be charged, but they are the best available public benchmark for what the lab work is worth.
| Test | Low | Average | High |
|---|---|---|---|
| Consumer ancestry-plus-health kit (23andMe list prices) | $99 | n/a | $199 |
| Clinical 163-gene panel sold direct to consumers (Marker by Labcorp) | n/a | $499 | n/a |
| Hereditary cancer panel, self-pay (Myriad MyRisk) | n/a | $249 | n/a |
| Carrier screening, prompt-pay cash price (Natera) | $249 | n/a | $349 |
| Pharmacogenomic panel, self-pay (GeneSight) | n/a | $330 | n/a |
| Financial-assistance floor (Natera, income-based) | $0 | n/a | $239 |
| Medicare rate, BRCA1/2 full sequence + dup/del (CPT 81162) | n/a | $1,824.88 | n/a |
| Medicare rate, hereditary breast cancer panel, 5+ genes (CPT 81432) | n/a | $1,303.95 | n/a |
| Medicare rate, expanded carrier panel, 15+ genes (CPT 81443) | n/a | $2,448.56 | n/a |
| Medicare rate, CYP2C19 / CYP2D6 drug metabolism (CPT 81225 / 81226) | $291.36 | n/a | $450.91 |
Sources: 23andMe’s comparison page lists Basic Ancestry at $99, Premium Ancestry at $149, and Premium Ancestry + Health at $199, with a Labor Day promotion running through September 7, 2026 that drops the first and third to $79 and $80. The $499 is Labcorp OnDemand’s listed price for the Marker by Labcorp Genetic Health Panel. Myriad tells MyRisk patients to call if their personalized cost estimate exceeds $249 per test. Natera states its prompt-pay cash price is typically $249 or $349 and that income-qualified patients can access a reduced cost of $0 to $239. GeneSight publishes a $330 reduced self-pay price. All Medicare figures come from the CMS 2026 Clinical Laboratory Fee Schedule Q3 public use file.
Two sources here appear to disagree by sevenfold on what a BRCA test is worth. They do not, really. The $249 and $499 numbers are prices a lab has chosen to charge a cash customer to grow volume. The $1,824.88 is what Medicare pays a lab for that code. The gap is a business decision, not a discount you negotiated.
What Drives the Price
Which of the four products you are actually buying
A hereditary cancer panel, a carrier screen, a pharmacogenomic panel, and a consumer ancestry kit are four different things. The cancer panel asks whether you inherited a variant that raises your own risk. The carrier screen asks what you might pass to a child. The pharmacogenomic panel asks how you metabolize certain drugs. The consumer kit is a genotyping product sold as a consumer good. Price quotes that mix these together are useless.
Whether you use insurance or deliberately opt out
This is the strangest feature of this market: opting out of insurance is frequently the cheaper move, and the labs say so openly. Myriad tells patients that those whose policy does not cover testing, who are uninsured, or who have a high deductible can choose to pay a fixed price by opting out of using insurance. GeneSight says its $330 self-pay option may be the most affordable choice for anyone whose estimated out-of-pocket cost is higher than $330. Natera generates an estimate and, if it exceeds its prompt-pay cash price, contacts you so you can choose the cash price instead.
Whether you meet testing guidelines
Coverage hinges on criteria, not on wanting the information. The USPSTF gives a B recommendation to BRCA risk assessment, counseling, and testing for women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or an ancestry associated with BRCA1/2 mutations. It gives a D recommendation against routine risk assessment, counseling, or testing for women whose history and ancestry are not associated with those mutations. That split is precisely where denials come from, and it is why the consumer-pay panels exist.
How many genes are on the panel
Medicare’s own schedule prices the genes. Full BRCA1/2 sequencing with deletion and duplication analysis (CPT 81162) is $1,824.88 in 2026, while sequencing alone without the rearrangement analysis (81163) is $468.00 and the three-founder-variant test (81212) is $440.00. A 5-or-more-gene hereditary breast cancer panel (81432) is $1,303.95. Bigger panel, bigger number, though cash prices flatten this out considerably.
Who sends you the bill
Labcorp Genetics, which now includes Invitae, says its billing team proactively contacts patients before a bill goes out if out-of-pocket responsibility is determined to exceed $100, with an automated call above $100 and a live follow-up call above $250. That is a useful thing to know: a large surprise bill from a genetics lab is often a conversation you are supposed to have before it is finalized, not after.
Clinical Panel vs. Consumer Kit
This is the distinction that decides whether the cheap option is actually an option.
A consumer kit like 23andMe’s health product is genotyping. Its BRCA report covers 44 selected variants in BRCA1 and BRCA2, and 23andMe’s own labeling says those variants do not represent the majority of BRCA1/BRCA2 variants in people of most ethnicities, that the report does not include variants in other genes linked to hereditary cancers, that absence of the tested variants does not rule out other variants affecting cancer risk, and that results should be confirmed in a clinical setting before taking any medical action. It is for over-the-counter use by adults and is explicitly not a substitute for recommended screening.
A clinical panel is sequencing, ordered by a clinician, with a lab report that goes into your medical record. Labcorp’s consumer-purchasable Marker Genetic Health Panel sits between the two worlds at $499: 163 genes covering hereditary cancer, cardiovascular, and metabolic conditions, blood drawn at a Labcorp patient service center, results in 10 to 21 days, a genetic counselor discussion included, HSA and FSA accepted. Labcorp is explicit that this test is meant for generally healthy adults and is not appropriate for people with a personal or strong family history of the conditions it covers, who should be getting a clinician-directed panel instead.
If your reason for testing is curiosity, the $99 to $199 kit is the right product. If your reason is a family history, the kit is the wrong product at any price, because a negative result from it does not mean what people assume it means.
Cash Price vs. Insurance
The honest summary is that most people with insurance who meet clinical criteria pay very little, and most people who do not meet criteria are better off never involving insurance at all.
On the covered side, Natera says more than 60% of patients billed to insurance have no out-of-pocket cost for its women’s health tests. Myriad says most commercial and federally funded plans cover hereditary cancer testing and that most patients face no out-of-pocket cost for MyRisk. GeneSight lists $0 as the typical out-of-pocket cost for patients on Medicare Part B, Medicare Advantage covered tests, and Medicaid. If you meet the USPSTF criteria described above, an ACA-compliant plan is required to cover risk assessment, counseling, and BRCA testing without cost sharing, which makes going through insurance clearly correct.
On the uncovered side, the calculation flips. Every one of these labs has built a fixed cash price specifically so that patients with high deductibles can bypass a claim: $249 at Myriad, $249 to $349 at Natera, $330 at GeneSight, $499 at Labcorp OnDemand. Running an expensive code through a deductible you will never meet is how a $249 test becomes a $1,300 bill.
The tradeoff is the same one that applies to any cash-pay care, including a Prenuvo whole-body scan or an out-of-pocket Cologuard kit: money you pay outside insurance does not count toward your deductible or out-of-pocket maximum. If you are close to meeting either, run the claim.
How to Pay Less
- Ask for the self-pay price by name before the test is run. The phrase that works is “what is your fixed self-pay price if I do not use insurance.” Every major lab has one, and none of them volunteer it first. Check any quote against our fair price checker.
- Do not let the estimate step go by. Myriad sends a personalized cost estimate before processing and tells patients to call within three days if it exceeds $249 per test. Natera messages you if its estimate is above its cash price. GeneSight contacts you before processing if your cost could exceed $330 and lets you cancel at no charge. These windows close, and Myriad notes it cannot change your payment method once results are ready.
- Apply for lab financial assistance, which is separate from hospital charity care. Natera lists an income-based reduced cost of $0 to $239 per test. Myriad, Ambry, and Labcorp all run their own income-based programs. Ask specifically for the lab’s financial assistance application, not a payment plan, first.
- Take the interest-free payment plan only after the discount. GeneSight offers up to 12 months interest-free on balances of $100 or more, and Myriad and Natera both offer interest-free plans. A payment plan on a price you never negotiated just spreads the wrong number over a year.
- If a genetics bill arrives unexpectedly, treat it like any other medical bill. Request an itemized hospital bill or lab statement showing the CPT codes billed, then compare against the CMS lab fee schedule figures above and use our medical bill negotiation guide. Large balances tied to a hospital-based lab may qualify under our hospital charity care guide.
- Never let a genetics balance age into collections while you are disputing it. These bills are frequently wrong about coverage criteria and frequently reversible. Our guide to medical bills in collections covers what to do if one slips through.
Bottom Line
Genetic testing costs $99 to $199 if what you want is a consumer ancestry-plus-health kit, $249 to $499 if what you want is a clinical panel and you pay cash, and close to nothing if you meet clinical criteria and have an ACA-compliant plan. The $1,824.88 Medicare pays for full BRCA1/2 sequencing is the ceiling on what the underlying lab work is worth, not what you should agree to pay.
The expensive mistake is not overpaying. It is buying the wrong product: a consumer kit that screens 44 BRCA variants when a family history called for a full sequencing panel, or a $1,300 insurance claim when a $249 cash price was sitting on the same lab’s website. Decide which of the four markets you are in, ask for that market’s fixed price, and the rest of the decision gets much simpler. This is a cost guide, not medical guidance, and whether any of these tests is right for you is a conversation for a clinician or a genetic counselor.